LuciOsim 80 MG (Osimertinib)

Basic Product Information of LuciOsim 80 MG (Osimertinib)

How LuciOsim 80 MG (Osimertinib) Works: Third-Generation Irreversible EGFR TKI Targeting Sensitizing Mutations and T790M Resistance

Osimertinib, the active ingredient in LuciOsim 80 MG, is the world’s first approved third-generation selective irreversible EGFR tyrosine kinase inhibitor (TKI) – a precision oncology drug class engineered to overcome the central limitation of all first- and second-generation EGFR TKIs by targeting not only the activating EGFR mutations that drive NSCLC tumor growth, but also the T790M gatekeeper resistance mutation (threonine-to-methionine substitution at amino acid position 790) responsible for approximately 50 to 60% of all acquired resistance events in NSCLC patients treated with first-generation EGFR TKIs such as gefitinib and erlotinib, or second-generation EGFR TKIs such as afatinib and dacomitinib.

The EGFR (epidermal growth factor receptor) protein is a receptor tyrosine kinase encoded by the EGFR gene on chromosome 7p11.2. When activated by epidermal growth factor (EGF) or transforming growth factor-alpha (TGF-alpha), EGFR triggers intracellular signaling cascades, including the RAS/MAPK pathway and the PI3K/AKT/mTOR pathway, that drive cell proliferation, survival, and metastasis. In NSCLC, activating mutations in the EGFR kinase domain – most commonly exon 19 deletions (accounting for approximately 45% of EGFR-mutant NSCLC) and exon 21 L858R substitutions (approximately 40%) – constitutively activate EGFR signaling independent of ligand binding, creating a state of continuous tumor cell proliferation that is exquisitely sensitive to EGFR TKI inhibition.

At the molecular level, osimertinib in LuciOsim 80 MG operates through a covalent, irreversible binding mechanism that fundamentally distinguishes it from the reversible competitive inhibition employed by all first- and second-generation EGFR TKIs. Osimertinib forms a covalent bond with Cys797 – the cysteine residue in the ATP-binding site of the EGFR kinase domain – permanently inactivating both mutant EGFR and T790M-mutant EGFR while preserving approximately 200-fold selectivity for mutant EGFR variants over wild-type EGFR (WT-EGFR). This mutant-selectivity over WT-EGFR is the pharmacological property that defines the third-generation TKI class and explains why osimertinib at 80 mg produces a substantially more favorable skin and gastrointestinal toxicity profile than first- and second-generation EGFR TKIs, which inhibit both WT-EGFR and mutant EGFR without meaningful selectivity, producing on-target skin rash, diarrhea, and paronychia at rates that frequently require dose reductions or treatment interruptions.

A defining clinical attribute of LuciOsim 80 MG is osimertinib’s demonstrated CNS penetration and intracranial antitumor activity. CNS metastases develop in approximately 25 to 40% of EGFR-mutant NSCLC patients over the course of their disease, and leptomeningeal disease is among the most clinically challenging and life-limiting manifestations of advanced NSCLC. Osimertinib’s lipophilic chemical structure enables it to cross the blood-brain barrier (BBB) at pharmacologically meaningful concentrations, delivering intracranial drug exposure sufficient to produce objective tumor responses in brain metastases and leptomeningeal disease.

In the FLAURA Phase 3 trial, osimertinib 80 mg reduced the risk of CNS progression by 52% compared to first-generation EGFR TKIs (CNS PFS hazard ratio of 0.48). Among the subset of patients with CNS metastases at baseline in FLAURA, osimertinib achieved a CNS objective response rate of 66% versus 43% for first-generation comparators. This intracranial efficacy is a pharmacologically unique property of osimertinib that no approved first- or second-generation EGFR TKI replicates at equivalent systemic doses, and it is a primary driver of osimertinib’s preferred first-line status across NCCN, ESMO, and ASCO guidelines for EGFR-mutant NSCLC regardless of baseline CNS involvement.

Osimertinib is metabolized primarily by CYP3A4 and to a lesser extent CYP3A5 in the liver, generating two active metabolites (AZ5104 and AZ7550) that contribute additional EGFR inhibitory activity. The plasma elimination half-life of osimertinib is approximately 48 hours, supporting once-daily oral dosing in LuciOsim 80 MG. Strong CYP3A4 inducers including rifampicin, phenytoin, carbamazepine, and St. John’s Wort reduce osimertinib plasma area under the curve (AUC) by approximately 78% and must be avoided during LuciOsim 80 MG treatment or replaced with non-inducing alternatives. Strong CYP3A4 inhibitors produce a clinically limited effect on osimertinib exposure at 80 mg and do not require dose adjustment in the majority of patients.

Osimertinib is a substrate for P-glycoprotein (P-gp) and BCRP efflux transporters; concurrent administration of strong P-gp inhibitors may increase systemic osimertinib exposure and warrants clinical monitoring. Healthcare providers establishing comprehensive EGFR-mutant NSCLC treatment programs can review the complete range of targeted oncology medicines at Mediaid Pharmacy’s osimertinib medicines range.

Approved Indications and Clinical Setting for LuciOsim 80 MG (Osimertinib)

Osimertinib, the active ingredient in LuciOsim 80 MG, carries reference-label indications across three approved clinical settings in NSCLC, each requiring confirmed EGFR mutation status by tissue or liquid biopsy companion diagnostic testing before treatment initiation. Across all three settings, the standard recommended dose is 80 mg once daily orally, with a dose reduction option to 40 mg once daily for adverse reaction management and a documented dose-response that makes the 80 mg standard dose the established efficacy benchmark across the FLAURA, AURA3, and ADAURA Phase 3 programs. Prescribers should confirm locally approved indications on the LuciOsim product label and current national and international NSCLC treatment guidelines before initiating treatment at 80 mg.

Safety Profile, Side Effects, and Precautions for LuciOsim 80 MG (Osimertinib)

The safety profile of osimertinib 80 mg in LuciOsim is well-characterized across the FLAURA, AURA3, and ADAURA Phase 3 trials involving more than 1,500 osimertinib-treated patients. Osimertinib’s mutant-EGFR selectivity (approximately 200-fold greater affinity for mutant vs. wild-type EGFR) produces a more favorable dermatological and gastrointestinal toxicity profile than first- and second-generation EGFR TKIs; however, the irreversible covalent binding mechanism introduces distinct risks – particularly interstitial lung disease (ILD) and QTc interval prolongation – that require proactive baseline assessment and ongoing monitoring throughout treatment with LuciOsim 80 MG. Grade 3 or higher adverse events occurred in approximately 23% of osimertinib-treated patients at the 80 mg dose in FLAURA, substantially lower than historical rates reported with afatinib and dacomitinib at full approved doses.

Who Should Use LuciOsim 80 MG (Osimertinib)?

LuciOsim 80 MG (Osimertinib) is prescribed for three precisely defined patient populations in adult NSCLC, each requiring confirmed EGFR mutation status before treatment initiation.

First, LuciOsim 80 MG is indicated as first-line therapy for adults with locally advanced or metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations confirmed by an approved or validated companion diagnostic test on either tumor tissue (preferred for highest sensitivity) or circulating tumor DNA (ctDNA) plasma biopsy. Patients in this first-line setting must have received no prior systemic therapy for locally advanced or metastatic disease, though prior adjuvant or neoadjuvant chemotherapy or EGFR TKI therapy for earlier-stage resected disease completed at least 12 months before advanced disease diagnosis does not exclude first-line LuciOsim 80 MG use. This patient group includes NSCLC patients with and without CNS metastases at diagnosis, given osimertinib’s confirmed blood-brain barrier penetration and intracranial activity.

Second, LuciOsim 80 MG is indicated for adults with locally advanced or metastatic NSCLC with confirmed T790M resistance mutation detected in tumor tissue or plasma ctDNA by a validated T790M companion diagnostic, who have progressed on or after first- or second-generation EGFR TKI therapy. T790M testing should be performed at the time of progressive disease on EGFR TKI therapy; patients with T790M-negative results on plasma ctDNA should undergo tumor tissue T790M testing before concluding T790M negativity, given the higher sensitivity of tissue biopsy.

Third, LuciOsim 80 MG is indicated as adjuvant treatment for adults with stage IB, II, or IIIA NSCLC with EGFR exon 19 deletion or exon 21 L858R mutation following complete tumor resection with or without prior adjuvant chemotherapy, administered for up to 3 years or until disease recurrence or unacceptable toxicity. Contraindications include confirmed hypersensitivity to osimertinib INN or any LuciOsim excipient. Relative contraindications requiring specialist benefit-risk evaluation before LuciOsim 80 MG initiation include: baseline QTc greater than 500 ms; baseline LVEF below 50%; active or prior ILD or pneumonitis; concurrent use of strong QTc-prolonging agents; and concurrent use of strong CYP3A4 inducers. For oncologists establishing EGFR-mutant NSCLC treatment programs or sourcing osimertinib alongside other targeted lung cancer therapies, the Mediaid Pharmacy oncology medicines collection and the dedicated lung cancer medicines portfolio offer a comprehensive selection with worldwide shipping.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciOsim 80 MG (Osimertinib)

Mediaid Pharmacy is a specialty oncology and pharmaceutical supplier with worldwide shipping to patients, oncology clinics, hospitals, and distributors across all global regions. LuciOsim 80 MG (Osimertinib), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available as 30 tablets per box and supplied with current pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. Thoracic oncology centers, lung cancer programs, pulmonology and oncology clinics, hospital formulary teams, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciOsim 80 MG Osimertinib stock availability, current pricing, and international delivery timelines to their country.

Buyers sourcing osimertinib 80 mg for EGFR-mutant NSCLC patients across first-line, second-line T790M-positive, or adjuvant treatment settings – or co-sourcing LuciOsim 80 MG with other targeted oncology therapies or lung cancer medicines in a single consolidated international shipment – can browse the complete lung cancer medicines collection and the broader oncology medicines portfolio at Mediaid Pharmacy before requesting a consolidated quotation covering all required products and quantities.

Why Choose LuciOsim 80 MG (Osimertinib) from Mediaid Pharmacy?

LuciOsim 80 MG (Osimertinib) provides oncologists, thoracic oncology specialists, and pulmonologists with the definitive third-generation EGFR TKI standard of care for EGFR-mutant NSCLC – the drug class that redefined the first-line treatment landscape through the FLAURA trial (median OS 38.6 months, the longest ever reported in a first-line EGFR-mutant NSCLC Phase 3 trial) and established osimertinib as the preferred single-agent EGFR TKI across all major global oncology guidelines, including NCCN, ESMO, and ASCO, for the first-line and T790M-positive second-line settings. LuciOsim 80 MG delivers three simultaneous clinical advantages that no first- or second-generation EGFR TKI can match: (1) mutant-EGFR selectivity approximately 200-fold greater than wild-type EGFR, producing a more favorable dermatological and GI tolerability profile; (2) T790M resistance mutation inhibition, the most common mechanism of acquired resistance to first- and second-generation EGFR TKIs, which affects approximately 50 to 60% of progressing patients on prior EGFR TKI therapy; and (3) confirmed CNS penetration and intracranial antitumor activity against brain metastases and leptomeningeal disease, with a 52% reduction in CNS progression risk versus first-generation comparators in FLAURA. These three properties together define osimertinib’s position as the preferred single-agent EGFR TKI in all settings where EGFR-targeted therapy is clinically appropriate, and they represent properties that the osimertinib 80 mg dose in LuciOsim fully delivers as a once-daily oral tablet requiring no injection, reconstitution, or clinic administration.

LuciOsim 80 MG is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and supplied in convenient 30-tablet packs. Mediaid Pharmacy supplies LuciOsim 80 MG with full product documentation, specialist supply coordination, and worldwide shipping. To source additional Lucius Pharmaceuticals-branded medicines or build a comprehensive NSCLC and oncology formulary alongside LuciOsim 80 MG, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the oncology medicines collection and contact the team for a personalized quotation covering all required products and quantities.

Frequently Asked Questions About LuciOsim 80 MG (Osimertinib)